OBJECTIVES: Caspofungin was non-inferior to liposomal amphotericin-B (L-AmB) in a recently conducted double-blind, randomized clinical trial (RCT) in 1095 hematology/oncology patients with persistent fever and neutropenia. Fewer patients developed nephrotoxicity with caspofungin than with L-AmB (2.6% vs. 11.5%, p < 0.001; Walsh et al., 2004). Based on the RCT data, cost and consequences of treatment with caspofungin versus L-AmB for empirical therapy of suspected systemic fungal infection were determined for the German hospital setting. METHODS: Our model is based on: (i) RCT nephrotoxicity rates; (ii) prolonged length of hospital stay due to nephrotoxicity in hematology/oncology patients in Europe (5.3 days, accounting perspective, 95%CI 1.6;9.1, p = 0.004; Ullmann et al., 2006); and (iii) bottom-up data on direct cost of hematology/oncology stay per day. Bootstrapping and MonteCarlo simulations were performed (SAS 9.1.3, WinBUGS 1.4.1). Calculations were based on patient-individualized doses per treatment episode per RCT treatment arm (Caspofungin 13 days; L-AmB 12.5 days; 70 kg patient), on both, official German price list, and German high-user hospital antifungal acquisition cost.
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. In HC state, all patients were admitted on average 3.4 times. Average LOS in DC and HC states was 11 days. 35% of HC patients needed hospice admission with an average LOS of 38 days. Common procedures include paracentesis (60%), sclerotherapy (50%), and TIPS (30%) in the DC state, and paracentesis (70%), radiofrequency ablation (15%), and ethanol injection (10%) in HC. CONCLUSIONS: RU and costs increase with disease progression: costs for the HC state are more than 30 times those for the CHB stage. Pfizer, Brussels, Belgium, 2 Health Economics and Outcomes Research, Brussels, Belgium OBJECTIVE: To assess, in a real life setting, the predictive validity of a health-economic model that had been applied for the Belgian reimbursement submission of voriconazole in proven and probable invasive aspergillosis. METHODS: An observational study was designed to prospectively collect health-economic data of patients with invasive aspergillosis starting treatment with voriconazole. The same direct costs as in the model were considered: costs for hospital stay, diagnostic procedures, treatment/monitoring of side effects, outpatient care and use of anti-fungal drug(s). Resource utilization, expressed in physical units, was multiplied with unit costs from the public payer's perspective. Costs were expressed as total costs and costs for switchers/non-switchers from initial voriconazole treatment. Effectiveness was expressed as clinical response and survival rate at day 84. RESULTS: A total of 115 patients were included. The average total cost was €14,153 (C.I.: €11,493; €16,812). This was below the cost predicted by the model (€21,298). The difference was mainly caused by shorter hospitalization in this study (9.59 days) than assumed in the model (29.4 days). On average the total cost for switchers/non-switchers amounted to €16,216/€10,067 in this study, which was below the estimated cost of €27,586/€18,783 in the model, mainly due to a lower hospitalization cost. The clinical response rate (50% successful outcome) as well as the infection related survival rate (86.7%) were in line with the ones applied in the model and reported from the clinical trials (52% and 87.5% respectively). The overall survival rate was lower compared to the model (58% vs. 70.8%), likely due to treating patients with poor prognosis at baseline who would have been excluded from the clinical trial. CONCLUSIONS: This observational study demonstrated that the health-economic model provided an overestimate of the real
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